Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 2
2005 3
2006 2
2007 1
2008 3
2009 2
2010 2
2011 4
2012 3
2013 3
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

23 results
Results by year
Filters applied: . Clear all
Page 1
EGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment.
Guérin O, Fischel JL, Ferrero JM, Bozec A, Milano G. Guérin O, et al. Among authors: fischel jl. Pharmaceuticals (Basel). 2010 Jul 19;3(7):2238-2247. doi: 10.3390/ph3072238. Pharmaceuticals (Basel). 2010. PMID: 27713352 Free PMC article. Review.
Epidermal growth factor receptor/angiogenesis dual targeting: preclinical experience.
Bozec A, Fischel JL, Milano G. Bozec A, et al. Among authors: fischel jl. Curr Opin Oncol. 2006 Jul;18(4):330-4. doi: 10.1097/01.cco.0000228737.78003.06. Curr Opin Oncol. 2006. PMID: 16721126 Review.
EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
Dassonville O, Bozec A, Fischel JL, Milano G. Dassonville O, et al. Among authors: fischel jl. Crit Rev Oncol Hematol. 2007 Apr;62(1):53-61. doi: 10.1016/j.critrevonc.2006.12.008. Epub 2007 Feb 26. Crit Rev Oncol Hematol. 2007. PMID: 17324578 Review.
Impact of erythropoietin on the effects of irradiation under hypoxia.
Lo Nigro C, Maffi M, Fischel JL, Monteverde M, Catarsi P, Tonissi F, Lattanzio L, Riba M, Etienne-Grimaldi MC, Formento P, Milano G, Merlano M. Lo Nigro C, et al. Among authors: fischel jl. J Cancer Res Clin Oncol. 2009 Nov;135(11):1615-23. doi: 10.1007/s00432-009-0609-1. Epub 2009 Jun 5. J Cancer Res Clin Oncol. 2009. PMID: 19499245
Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.
Guérin O, Etienne-Grimaldi MC, Monteverde M, Sudaka A, Brunstein MC, Formento P, Lattanzio L, Maffi M, Tonissi F, Ortholan C, Pagès G, Fischel JL, Lo Nigro C, Merlano M, Milano G. Guérin O, et al. Among authors: fischel jl. Urol Oncol. 2013 Nov;31(8):1567-75. doi: 10.1016/j.urolonc.2012.03.003. Epub 2012 May 17. Urol Oncol. 2013. PMID: 22608542
Emerging molecular targeted therapies in the treatment of head and neck cancer.
Bozec A, Peyrade F, Fischel JL, Milano G. Bozec A, et al. Among authors: fischel jl. Expert Opin Emerg Drugs. 2009 Jun;14(2):299-310. doi: 10.1517/14728210902997947. Expert Opin Emerg Drugs. 2009. PMID: 19519286 Review.
Gefitinib-trastuzumab combination on hormone-refractory prostate cancer xenograft.
Formento P, Hannoun-Levi JM, Gérard F, Mazeau C, Fischel JL, Etienne-Grimaldi MC, Gugenheim J, Milano G. Formento P, et al. Among authors: fischel jl. Eur J Cancer. 2005 Jul;41(10):1467-73. doi: 10.1016/j.ejca.2005.03.021. Eur J Cancer. 2005. PMID: 15919200
Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
Chefrour M, Milano G, Formento P, Giacometti S, Denden A, Renée N, Iliadis A, Fischel JL, Ciccolini J. Chefrour M, et al. Among authors: fischel jl. Fundam Clin Pharmacol. 2012 Aug;26(4):530-7. doi: 10.1111/j.1472-8206.2011.00945.x. Epub 2011 May 30. Fundam Clin Pharmacol. 2012. PMID: 21623901
Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study.
Sudaka A, Susini A, Lo Nigro C, Fischel JL, Toussan N, Formento P, Tonissi F, Lattanzio L, Russi E, Etienne-Grimaldi MC, Merlano M, Milano G. Sudaka A, et al. Among authors: fischel jl. Invest New Drugs. 2013 Feb;31(1):59-65. doi: 10.1007/s10637-012-9834-6. Epub 2012 Jun 20. Invest New Drugs. 2013. PMID: 22714791
Combination of docetaxel and vandetanib in docetaxel-sensitive or resistant PC3 cell line.
Monteverde M, Tonissi F, Fischel JL, Etienne-Grimaldi MC, Milano G, Merlano M, Lo Nigro C. Monteverde M, et al. Among authors: fischel jl. Urol Oncol. 2013 Aug;31(6):776-86. doi: 10.1016/j.urolonc.2011.03.018. Epub 2011 Jul 27. Urol Oncol. 2013. PMID: 21795074
23 results
Jump to page
Feedback